Citius Oncology, INC. (CTOR) — 10-Q Filings

10-Q Filings (5)

• Citius Oncology's Losses Mount, Cash Dwindles Amid Going Concern Doubts — Aug 12, 2025 Risk: high
  Citius Oncology, Inc. (CTOR) reported a net loss of $19,764,713 for the nine months ended June 30, 2025, a significant increase from the $14,335,799 net loss fo
• Citius Oncology Files Q1 2025 10-Q Report — May 14, 2025 Risk: low
  Citius Oncology, Inc. filed its 10-Q for the quarterly period ended March 31, 2025. The company, formerly known as TenX Keane Acquisition, is incorporated in De
• Citius Oncology Files Q4 2024 10-Q Report — Feb 14, 2025 Risk: low
  Citius Oncology, Inc. filed its quarterly report on Form 10-Q for the period ended December 31, 2024. The company, previously known as TenX Keane Acquisition un
• CITIUS ONCOLOGY Files Q2 2024 10-Q — Aug 9, 2024 Risk: medium
  CITIUS ONCOLOGY, INC. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as TenX Keane Acquisition, is in the pharmaceutical prepar
• TenX Keane Acquisition Files Q1 2024 10-Q — May 20, 2024 Risk: low
  TenX Keane Acquisition filed its 10-Q for the period ending March 31, 2024. The company, operating in pharmaceutical preparations, reported its financial status

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX